MedTrace Logo

The HELlenic Thoracic Society Initiative for CΟPD and CVD

NCT06595784 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2025-09-10

No results posted yet for this study

Summary

COPD is one of the most common respiratory diseases in Greece, and maybe more than half a million Greek citizens suffer both from COPD and CVD, however their characteristics and management remain unknown. HELICOPD is a national, multicenter, prospective, non-interventional study designed to contribute to better understanding and depicting the demographic and clinical characteristics of this population, the COPD- and CVD-related adverse events in a two-years period, their quality of life and the healthcare resources use. The study is initiated and coordinated by the Hellenic Thoracic Society.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Cardiovascular Diseases (CVD)

Sponsors & Collaborators

  • Hellenic Thoracic Society

    lead OTHER

Principal Investigators

  • Georgios Hillas · 5th Pulmonary Department, "Sotiria" Chest Diseases Hospital, Athens, Greece

  • Paschalis Steiropoulos · Department of Respiratory Medicine, Medical School, Democritus University of Thrace, University General Hospital

Eligibility

Min Age
35 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-15
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06595784 on ClinicalTrials.gov